|
|Section2= |Section3= }} Licofelone is a dual COX/LOX inhibitor being considered as a treatment for osteoarthritis and which is under development by Merckle GmbH with partners Alfa Wassermann and Lacer. Licofelone is both an analgesic and an anti-inflammatory. Inhibition of 5-LOX may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase). Licofelone is the first drug to inhibit both. It has passed the phase III trials.〔http://www.drugdevelopment-technology.com/projects/licofelone/〕 ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Licofelone」の詳細全文を読む スポンサード リンク
|